Intellectual Property

Intellectual Property Law360 provides breaking news and analysis on IP law. Coverage includes high-stakes cases involving patents, copyrights, trademarks, trade secrets, and other forms of IP, as well as policy developments and licensing deals.



Sign up for a 7-day FREE trial today!



Latest News in Intellectual Property

  • June 21, 2024

    Quinn Emanuel Rips Columbia's 'Utterly Meritless' Filing Bid

    Quinn Emanuel Urquhart & Sullivan LLP told the Federal Circuit on Friday that Columbia University's bid to introduce a former Norton Lifelock computer scientist's declaration claiming the company's former lawyers at the firm are lying about his refusal to testify in the school's decade-long $600 million patent case is "utterly meritless."

  • June 21, 2024

    Apple Won't Offer AI Tools In EU Due To Regulatory Concerns

    Apple confirmed Friday that the tech giant isn't planning on releasing new artificial intelligence features in the European Union this year due to "regulatory uncertainties" involving the bloc's new Digital Markets Act and the potential security risks that complying with the DMA could pose to Apple users.

  • June 21, 2024

    Drug Cos., IP Attys Back Cellect In High Court Efforts

    A petition by patent litigation outfit Cellect that is looking to persuade the U.S. Supreme Court to wade into a double patenting dispute has drawn support from even more lawyers as well as a handful of major drugmakers and small tech companies like Sonos.

  • June 21, 2024

    Drugmakers Decline To Drop Patent Listings After FTC Letters

    The eight pharmaceutical companies that the Federal Trade Commission warned in April may have improperly listed patents for its products in a key federal database have chosen not to remove any patents or otherwise alter their listings, according to a document released Friday.

  • June 21, 2024

    After Fed. Circ. Win, Bausch Sues Alvogen Over Drug Patents

    Bausch's Salix Pharmaceuticals has launched a lawsuit against Alvogen's Norwich Pharmaceuticals unit in a New Jersey federal court, claiming that its planned generic version of Xifaxan, a blockbuster diarrhea and brain disorder drug, infringes a set of patents.

See more Intellectual Property news

Intellectual Property

Areas of Coverage

  • LITIGATION
  • Infringement suits over patents, copyrights, and trademarks
  • Patent Trial and Appeal Board disputes
  • Abbreviated New Drug Application (ANDA) litigation
  • Section 301 cases
  • Trade secrets disputes
  • Licensing and royalty fights
  • Right-of-publicity suits
  • Antitrust disputes involving IP issues
  • AGENCIES
  • U.S. Patent and Trademark Office
  • U.S. Copyright Office
  • U.S. International Trade Commission
  • World Intellectual Property Organization
  • POLICY & REGULATION
  • Patent reform legislation and related bills in Congress
  • Efforts to streamline international intellectual property law
  • ENFORCEMENT
  • Piracy and counterfeiting actions
  • International trade disputes involving IP issues
  • PROFILES
  • Personnel moves
  • Profiles of IP practices

Readership

  • Intellectual property lawyers at top law firms
  • Corporate counsel and compliance officers at Fortune 1000 companies
  • Executives and attorneys in the life sciences, technology, and other IP-focused industries
  • Information experts at law firms, agencies, and companies
  • Policymakers at federal and state agencies
  • Judges and court staff across the U.S.
  • Professors, students, and library staff at every accredited law school in the U.S.
  • Attorney and law firm marketing professionals
Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!